Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (East), Mumbai – 400063 India

Tel.: (91-22) 43244324 / 1234 Fax.: (91-22) 43244343

CIN: L24230GJ1993PLC019050, www.sunpharma.com



June 8, 2018

National Stock Exchange of India Ltd,

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051.

NSE Code – SUNPHARMA

BSE Ltd,

Market Operations Dept. P. J. Towers, Dalal Street, Mumbai - 400 001.

BSE Code-524715

Sub: Clarification /Confirmation on news item appearing in "Media/Publication" Dear Sirs,

We hereby submit our responses as follows with reference to your emails dated today, June 8, 2018 seeking clarification on recent news item in "www.moneycontrol.com" dated June 08, 2018 captioned "No re-inspection at Sun Pharma's Halol unit sends stock soaring 9%".

Please note that as indicated on the US FDA website, the February 2018 GMP inspection of Sun Pharmaceutical Industries Ltd.'s Halol facility in Gujarat, India, has been classified by the US FDA as VAI (Voluntary Action Indicated) status. We are awaiting the receipt of the Establishment Inspection Report (EIR) from the US FDA for the above referred GMP inspection conducted at our Halol facility from February 12-23, 2018. As and when we receive the EIR, we shall inform the exchanges immediately.

Further, please find our responses below to the specific queries raised by you .

Query: Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading? If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under regulation 30 of the SEBI (LODR) Regulations, 2015.

Response: No

Query: Whether such negotiations were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order from the start of negotiations till date.

Response: Not Applicable

Registered Office: SPARC, Tandalja, Vadodara - 390 012. India

Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (East), Mumbai – 400063 India

Tel.: (91-22) 43244324 / 1234 Fax.: (91-22) 43244343

CIN: L24230GJ1993PLC019050, www.sunpharma.com



Query: Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading? If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Response: No

Kindly let us know in case you require any further clarification.

Yours faithfully,

For Sun Pharmaceutical Industries Limited,

Ashok I Bhuta

Compliance Officer

Registered Office: SPARC, Tandalja, Vadodara - 390 012. India